Pay in 4 interest-free payments of $7.20 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
After 48 weeks, 36%-48% of subjects receiving 8 mg and 12 mg doses achieved 25% weight reduction, with no participants in the placebo group reaching this level
For a deeper understanding of how peptide blends are formulated, see the PubMed research on peptide combination studies
Tirzepatide stimulates GLP-1 and GIP receptors, enhancing insulin secretion, slowing gastric emptying, and promoting satiety
Some people see changes quickly, others gradually
they are not intended for human consumption, medical, diagnostic, cosmetic, veterinary or any other non-research use
These internal MEDVi data and patient-reported outcomes do not establish that compounded semaglutide or tirzepatide are safe or effective for every patient, and they should not be viewed as a substitute for FDA-reviewed clinical trial evidence
